GSK plc
CIK: 1131399
New Positions
0
Increased
0
Exit Positions
0
Holdings (13)
Q3 2026 13F, quarter ended Sep 30, 2026, filed Nov 5, 2026
- CRSP
CRISPR THERAPEUTICS AG
$144.3M
2.61M sh29.03%-19.0% - VIR
VIR BIOTECHNOLOGY INC
$95.6M
8.55M sh19.23%+0.0% - WVE
WAVE LIFE SCIENCES INC
$67.51M
18.25M sh13.58%+0.0% - BNTX
BIONTECH SE
$65.72M
668,526 sh13.22%-24.9% - IDYA
IDEAYA BIOSCIENCES INC
$51.23M
1.33M sh10.31%+0.0% - CYTK
CYTOKINETICS INC
$22.44M
340,434 sh4.51%+0.0% - LYEL
LYELL IMMUNOPHARMA INC
$14.81M
1.51M sh2.98%+0.0% - SPRO
SPERO THERAPEUTICS INC
$11.12M
9.19M sh2.24%+0.0% - NKTX
NKARTA INC
$8.25M
3.15M sh1.66%+0.0% - FULC
FULCRUM THERAPEUTICS INC
$6.61M
1.79M sh1.33%+0.0% - BCYC
BICYCLE THERAPEUTICS PLC
$5.63M
1.53M sh1.13%+0.0% - RGNX
REGENXBIO INC
$2.04M
271,456 sh0.41%+0.0% - CVRX
CVRX INC
$1.76M
1.01M sh0.35%+0.0%
| Security | Shares | Value | Change | Weight | Period |
|---|---|---|---|---|---|
 CRSP CRISPR THERAPEUTICS AG | 2.61M | $144.3M | -19.0% | 29.03% | Q3 2026 |
 VIR VIR BIOTECHNOLOGY INC | 8.55M | $95.6M | +0.0% | 19.23% | Q3 2026 |
 WVE WAVE LIFE SCIENCES INC | 18.25M | $67.51M | +0.0% | 13.58% | Q3 2026 |
 BNTX BIONTECH SE | 668,526 | $65.72M | -24.9% | 13.22% | Q3 2026 |
 IDYA IDEAYA BIOSCIENCES INC | 1.33M | $51.23M | +0.0% | 10.31% | Q3 2026 |
 CYTK CYTOKINETICS INC | 340,434 | $22.44M | +0.0% | 4.51% | Q3 2026 |
 LYEL LYELL IMMUNOPHARMA INC | 1.51M | $14.81M | +0.0% | 2.98% | Q3 2026 |
 SPRO SPERO THERAPEUTICS INC | 9.19M | $11.12M | +0.0% | 2.24% | Q3 2026 |
 NKTX NKARTA INC | 3.15M | $8.25M | +0.0% | 1.66% | Q3 2026 |
 FULC FULCRUM THERAPEUTICS INC | 1.79M | $6.61M | +0.0% | 1.33% | Q3 2026 |
 BCYC BICYCLE THERAPEUTICS PLC | 1.53M | $5.63M | +0.0% | 1.13% | Q3 2026 |
 RGNX REGENXBIO INC | 271,456 | $2.04M | +0.0% | 0.41% | Q3 2026 |
 CVRX CVRX INC | 1.01M | $1.76M | +0.0% | 0.35% | Q3 2026 |
1-13 of 13 holdings
Sector Allocation
SEC Filings
| Form | Description | Filed |
|---|---|---|
About GSK plc
GSK plc is an Investment Adviser that reports its US-listed stock and option positions to the SEC on Form 13F (CIK 1131399). Signal8 holds 10 13F filings from it.
Its most recent 13F holdings report covers Q3 2026 (the quarter ended Sep 30, 2026) and was filed on Nov 5, 2026. That report lists 13 securities, not counting options, the same number as in Q2 2026.
Its five largest reported positions, in order, are CRISPR THERAPEUTICS AG (CRSP), VIR BIOTECHNOLOGY INC (VIR), WAVE LIFE SCIENCES INC (WVE), BIONTECH SE (BNTX) and IDEAYA BIOSCIENCES INC (IDYA). The next five are CYTOKINETICS INC (CYTK), LYELL IMMUNOPHARMA INC (LYEL), SPERO THERAPEUTICS INC (SPRO), NKARTA INC (NKTX) and FULCRUM THERAPEUTICS INC (FULC).
Recent 13F filings by GSK plc
- Q3 2026: 13F-HR filed Nov 5, 2026, listing 13 securities.
- Q2 2026: 13F-HR filed Aug 13, 2026, listing 13 securities.
- Q1 2026: 13F-HR filed May 14, 2026, listing 13 securities.
- Q4 2025: 13F-HR filed Feb 12, 2026, listing 15 securities.